Assenagon Asset Management S.A. Macrogenics Inc Transaction History

Assenagon Asset Management S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$4.62 - $7.54 $3.44 Million - $5.61 Million	-743,833 Reduced 49.84%	748,679 $4.01 Million
Q4 2022 Jan 12, 2023	SELL	$3.34 - $6.98 $1.02 Million - $2.13 Million	-305,746 Reduced 17.0%	1,492,512 $10 Million
Q3 2022 Oct 27, 2022	SELL	$3.01 - $5.22 $7,239 - $12,554	-2,405 Reduced 0.13%	1,798,258 $6.22 Million
Q2 2022 Jul 27, 2022	BUY	$2.25 - $9.99 $1.23 Million - $5.46 Million	547,004 Added 43.63%	1,800,663 $5.31 Million
Q1 2022 Apr 25, 2022	BUY	$8.12 - $16.9 $8.76 Million - $18.2 Million	1,079,273 Added 618.9%	1,253,659 $11 Million
Q4 2021 Feb 01, 2022	BUY	$15.91 - $21.88 $2.4 Million - $3.3 Million	150,850 Added 640.93%	174,386 $2.8 Million
Q3 2021 Oct 19, 2021	SELL	$19.74 - $28.7 $47,454 - $68,994	-2,404 Reduced 9.27%	23,536 $493,000
Q2 2021 Jul 15, 2021	BUY	$20.49 - $35.63 $82,349 - $143,196	4,019 Added 18.33%	25,940 $697,000
Q1 2021 Apr 26, 2021	BUY	$18.99 - $33.2 $416,279 - $727,777	21,921 New	21,921 $698,000
Q3 2020 Oct 07, 2020	SELL	$24.69 - $31.6 $4.35 Million - $5.56 Million	-176,072 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$5.2 - $29.12 $915,574 - $5.13 Million	176,072 New	176,072 $4.92 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.